Nanomedicine has offered new solutions for cancer diagnosis and therapy. However, the survival improvement offered by current nanomedicines remains modest. To further advance the development of nanomedicines, it is crucial to investigate and understand the correlation between the properties of nanomedicines (e.g., particle size) and biological responses to lay the foundation for the design of next-generation nanomedicines with optimum efficacy against cancers. Here, we report the development of size-controlled, monodisperse drug-silica nanoconjugates and systematically evaluation of their size effect on antitumor efficacy in both primary and metastatic tumor models. We find that the 50-nm nanoconjugate has the most optimal antitumor efficacy compared to 200- and 20-nm nanoconjugates. The silica-drug nanoconjugates show great potential for clinical applications because of their long-term biocompatibility and their capability of in vivo clearance.

Development of silica nanoconjugates for primary and metastatic cancer treatment

246th National Meeting (2013)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.